Check Capital Management Inc. CA Boosts Holdings in Cardlytics, Inc. (NASDAQ:CDLX)

Check Capital Management Inc. CA grew its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 10.4% during the third quarter, HoldingsChannel reports. The firm owned 50,650 shares of the company’s stock after purchasing an additional 4,775 shares during the quarter. Check Capital Management Inc. CA’s holdings in Cardlytics were worth $162,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Canton Hathaway LLC raised its position in shares of Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock worth $37,000 after acquiring an additional 2,200 shares in the last quarter. SG Americas Securities LLC bought a new position in Cardlytics in the third quarter worth $45,000. Creative Planning raised its holdings in Cardlytics by 35.4% in the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after purchasing an additional 7,721 shares in the last quarter. XTX Topco Ltd purchased a new position in Cardlytics during the second quarter valued at $107,000. Finally, Quest Partners LLC boosted its holdings in shares of Cardlytics by 160.4% during the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after buying an additional 11,061 shares in the last quarter. 68.10% of the stock is owned by institutional investors.

Insider Transactions at Cardlytics

In other news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 43,573 shares of company stock worth $151,612 over the last three months. 4.40% of the stock is currently owned by company insiders.

Cardlytics Price Performance

CDLX stock opened at $3.60 on Friday. The stock’s 50 day simple moving average is $3.73 and its 200 day simple moving average is $6.48. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12-month low of $2.89 and a 12-month high of $20.52.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. During the same period last year, the firm posted ($0.26) earnings per share. Cardlytics’s revenue was down 15.1% compared to the same quarter last year. Research analysts expect that Cardlytics, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CDLX. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Evercore ISI began coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price for the company. Northland Securities downgraded Cardlytics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $7.00 to $5.00 in a research note on Friday, August 16th. Bank of America cut Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $4.00 to $3.50 in a research note on Thursday, August 15th. Finally, Northland Capmk cut Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Cardlytics presently has an average rating of “Hold” and an average target price of $6.92.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.